The regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.Flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.